Drug Profile

S 005151

Alternative Names: Redasemtide; S-005151

Latest Information Update: 31 May 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator StemRIM
Developer Shionogi
Class Peptides; Skin disorder therapies; Vascular disorder therapies
Mechanism of Action Stem cell modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Epidermolysis bullosa
New Molecular Entity Yes

Highest Development Phases

Phase II Epidermolysis bullosa; Ischaemic stroke

Most Recent Events

24 May 2023 S 005151 receives Orphan Drug status for Epidermolysis bullosa in Japan
10 Apr 2023 Efficacy data from a phase II trial in Ischaemic stroke released by Shionogi
10 Apr 2023 Shionogi initiates enrolment in a global phase II trial for Ischaemic stroke in Japan

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com